Exits

Name Descriptionsort icon Event Date Acquired By
<a href="http://www.bindtherapeutics.com/" target="_blank">BIND Therapeutics, Inc.</a> Developing Accurins, its novel targeted therapeutics. IPO 2013
Seres Therapeutics Developing a novel class of biological drugs that are designed to treat disease by restoring the function of a dysbiotic microbiome. IPO 2015
<a href="http://www.gilead.com/" target="_blank">CGI Pharmaceuticals, Inc.</a> Developing small molecule therapeutics for multiple oncology and immunology-based indications Acquired 2010 <a href="http://www.gilead.com/" target="_blank">Gilead</a>
<a href="http://www.appliedbiosystems.com" target="_blank">PerSeptive BioSystems</a> Developer of high-technology purification, analysis and synthesis products Acquired 1998 <a href="http://www.appliedbiosystems.com" target="_blank">Applied Biosystems</a>
Celexion LLC Developed powerful platform technologies. Acquired 2015 <a href="http://www.agenusbio.com/" target="_blank">Agenus</a>
<a href="http://www.hologic.com" target="_blank">CYTYC</a> Design, development, manufacturing, and marketing of medical devices focused on women's health IPO 1996
<a href="http://tphase.com/home" target="_blank">Tetraphase Pharmaceuticals, Inc.</a> Creating novel antibiotics for serious and life-threatening multidrug-resistant (MDR) bacterial infections. IPO 2013
<a href="http://www.concertpharma.com" target="_blank">Concert Pharmaceuticals, Inc.</a> Applying the company’s DCE Platform® (deuterated chemical entity platform) to create novel and differentiated small molecule drugs. IPO 2014